Aim of Service. To provide holistic pharmaceutical care to patients receiving OST and promote patient’s recovery by: • Providing close liaison with prescriber and treatment services; • Dispensing OST as prescribed according to the patient’s assessed needs; • Ensuring each supervised self administration dose is consumed in accordance with the appropriate Standard Operating Procedure (SOP); • Monitoring the patient’s response to prescribed treatment; • Providing general health advice including pharmaceutical public health services and signposting for access to further advice or assistance; • Promoting patient safety and appropriate harm minimisation strategies. To reduce the risk to individuals and local communities of: • Overuse or underuse of medicines; and • Diversion of prescribed medicines.
Aim of Service. To provide quality holistic pharmaceutical care to patients receiving disulfiram and promote recovery by: • Providing close liaison with prescriber and treatment services. • Providing a disulfiram service as per Health Board (HB) guidance; in standard circumstances always using the breathalyser as the initial guide for supervision and contacting Alcohol and Drug Recovery Services (ADRS) promptly (within 24 hours) with any single missed dose, any single positive reading or missed instalments. • Dispensing disulfiram as prescribed while adhering to protocol, including during medicine shortages. • Ensuring each supervised self-administration dose is consumed in accordance with the appropriate store Standard Operating Procedure (SOP) • Monitoring the on going response to prescribed treatment. • Providing general health advice including pharmaceutical public health services and signposting for access to further advice or assistance. • Promoting patient safety and appropriate harm minimisation strategies.
Aim of Service. Patients with a confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) may occasionally experience deterioration in their condition. Most will be familiar with the onset of the associated symptoms which can lead to hospitalisation if the medication required to alleviate the condition is not readily available. This service seeks to ensure that patients requiring medication to treat an exacerbation of COPD have reasonable access to supplies of appropriate medicines and that suitable advice is available on their use.
Aim of Service. To ensure that patients requiring medication for palliative care and their carers have reasonable access to supplies of appropriate medicines at all times, and that suitable advice is available on their use.
Aim of Service. This locally commissioned service was developed in recognition of the unfunded work undertaken in General Practice.
Aim of Service. An anti-coagulation monitoring service is designed to be one that should be available to all registered patients including those that are housebound and require domiciliary visits. Practices are required to liaise with community services to ensure there is no gap in service provision for all patients.
Aim of Service. Both ABPM and HBPM permits the non-invasive measurement of blood pressure over a prolonged period (usually 24 hours) and have been in NICE guidelines for adult hypertension for many years. HBPM is increasingly popular and convenient for patients and its use should be supported and encouraged to confirm diagnosis and in self-monitoring. This service is intended for:
Aim of Service. ECG recordings and interpreting can be done by GPs in the community, thereby reducing the need to refer patients to Secondary or Acute units. This enables patients to have care closer to home and ensures that the time delay from request to investigation is minimal. This service aims to:
Aim of Service. This locally commissioned service will fund: • The administration and monitoring of denosumab injections for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures.
Aim of Service. This locally commissioned service will fund: • The administration of depot antipsychotic injections (as recommended in the ICB formulary) for maintenance therapy of schizophrenia and other psychoses and the associated physical monitoring,
